Tag: Akcea

NICE Published Final Guideline for Akcea Nerve Damage Drug

drug
Akcea Therapeutics UK has announced that the National Institute for Health and Care Excellence (NICE) has published a final guideline for its nerve damage drug, Tegsedi (inotersen). The Highly Spec...

EMA Recommended First Med for FCS

EMA
The European Medicines Agency has recommended granting a conditional marketing authorisation (CMA) for Waylivra (volanesorsen), the first medicine for the treatment of the familial chylomicronaemia sy...

Novartis to Get Rights of Ionis’ CVD Treatment

Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeut...

NICE declines two hATTR Drugs

NICE has rejected two pioneering drugs for the rare inherited condition, hereditary transthyretin-related amyloidosis (hATTR) in first draft guidance. The cost-effectiveness body had been using an ...